newdrugapprovals.org
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
IBRUTINIB 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one SUNNYVALE, Calif., April 8, 2013 Pharmacyclics, Inc. announced today that the U.S. Food …